



## MONTHLY HIGHLIGHTS

- Average daily turnover of ETFs and L&I Products in March 2021 was \$7.7 billion, down 19% from February 2021.
- Market capitalisation of ETFs and L&I Products at the end of March 2021 was \$393 billion, down 2% from February 2021.
- 4 new ETFs were listed in March including Harvest CSI 300 ESG Leaders Index ETF (3108 / 83108) by Harvest Global Investment Limited – listed on 10 March 2021.
- Global X China Global Leaders ETF (3050) and Global X China Innovator Active ETF (3058), both by Mirae Asset Global Investments (HK) Limited, commenced trading on 11 March 2021.
- The first purely Hong Kong-listed biotech ETF – ChinaAMC Hang Seng Hong Kong Biotech Index ETF (3069) by China Asset Management (Hong Kong) Limited – commenced trading on 18 March 2021.

### Average Daily Turnover (ADT) & Market Capitalisation (MC)




### Monthly Net Fund Flow of ETFs and L&I Products



## ASSET CLASS COMPARISON

### ETF Price Return for the month of March 2021 (By Asset Class)



- Several broad market ETFs investing in the Asia Pacific region, especially Singapore, led performance in March on the back of an improved global recovery outlook.
- ETFs investing in China's new economy stocks continued to underperform due to the reversal of the "new economy" investment theme, with China Internet and cloud computing ETFs suffering the worst setback.

## NEWLY LISTED PRODUCTS

### Harvest CSI 300 ESG Leaders Index ETF (3108 / 83108)

#### Investment objective

The ETF seeks to provide investment results that, before fees and expenses, closely correspond to the performance of the CSI 300 Harvest ESG Leaders Index, which is designed to represent the performance of A-Shares of companies selected from the CSI 300 Index that demonstrate leading ESG profiles within their respective sectors.

#### Key information

Issuer	Harvest Global Investment Limited
Fund size as of end-Mar	RMB63.30M
Listing Date	10 Mar 2021
Benchmark	CSI 300 Harvest ESG Leaders Index
Trading currency	HKD
NAV as of end-Mar	HK\$11.35
Closing price as of end-Mar	HK\$11.47
Lot size	100
Ongoing charges figure	1.35%

### Global X China Global Leaders ETF (3050)

#### Investment objective

The underlying index of the ETF tracks the performance of securities issued by Chinese companies that have a global presence and a demonstrable track record as globally competitive players within their respective industries. Such companies must derive >25% of total sales from revenue generated outside of Mainland China, Hong Kong and Macau.

#### Key information

Issuer	Mirae Asset Global Investments (Hong Kong) Limited
Fund size as of end-Mar	RMB35.31M
Listing Date	11 Mar 2021
Benchmark	FactSet China Global Leaders Index (net total return)
Trading currency	HKD
NAV as of end-Mar	HK\$59.78
Closing price as of end-Mar	HK\$59.92
Lot size	50
Ongoing charges figure	0.68%

### Global X China Innovator Active ETF (3058)

#### Investment objective

The ETF aims to achieve long term capital growth by primarily investing in companies which are headquartered or incorporated in Mainland China, Hong Kong or Macau and are involved in the provision of innovative products and/or services.

#### Key information

Issuer	Mirae Asset Global Investments (Hong Kong) Limited
Fund size as of end-Mar	RMB49.90M
Listing Date	11 Mar 2021
Trading currency	HKD
NAV as of end-Mar	HK\$59.13
Closing price as of end-Mar	HK\$58.90
Lot size	50
Ongoing charges figure	0.75%

### ChinaAMC Hang Seng Hong Kong Biotech Index ETF (3069)

#### Investment objective

The underlying index of the ETF reflects the overall performance of the biotech companies that are listed on the Main Board of the Stock Exchange of Hong Kong, including stocks listed through the new Listing Rules Chapter 18A.

#### Key information

Issuer	China Asset Management (Hong Kong) Limited
Fund size as of end-Mar	HK\$1.50B
Listing Date	18 March 2021
Benchmark	Hang Seng Hong Kong-Listed Biotech Index
Trading currency	HKD
NAV as of end-Mar	HK\$23.44
Closing price as of end-Mar	HK\$23.30
Lot size	100
Ongoing charges figure	0.71%

## ETFs OF THE MONTH The three best-performing ETFs in March 2021

### 1 Xtrackers MSCI Singapore UCITS ETF (3065)

#### Investment objective

The underlying index of the ETF is designed to reflect the performance of the listed shares of large-, medium- and small-sized companies from Singapore.

#### Key information

Issuer	DWS Investment S.A.
Fund size as of end-Mar	US\$3.52M
Listing Date	11 Apr 2013
Benchmark	MSCI Singapore Investable Market Total Return Net Index
Trading currency	HKD
NAV as of end-Mar	HK\$12.00
Closing price as of end-Mar	HK\$12.00
Lot size	500
Ongoing charges figure	0.50%

### 2 Xtrackers MSCI Russia Capped Swap UCITS ETF (3027)

#### Investment objective

The underlying index of the ETF reflects the performance of the listed shares of large and medium sized companies from Russia.

#### Key information

Issuer	DWS Investment S.A.
Fund size as of end-Mar	US\$6.05M
Listing Date	24 Feb 2010
Benchmark	MSCI Russia Capped Index
Trading currency	HKD
NAV as of end-Mar	HK\$22.83
Closing price as of end-Mar	HK\$22.86
Lot size	125
Ongoing charges figure	0.65%

### 3 BMO MSCI Europe Quality Hedged to USD ETF (3165)

#### Investment objective

The underlying index aims to capture the performance of quality growth stocks from the MSCI Europe Index using a quality strategy defined by MSCI Inc., based on 3 main fundamental variables: high return on equity, stable year-over-year earnings growth and low financial leverage.

#### Key information

Issuer	BMO Global Asset Management (Asia) Limited
Fund size as of end-Mar	HK\$55.46M
Listing Date	18 Feb 2016
Benchmark	MSCI Europe Quality 100% Hedged to USD Index
Trading currency	HKD
NAV as of end-Mar	HK\$14.22
Closing price as of end-Mar	HK\$14.22
Lot size	200
Ongoing charges figure	0.50%

## ETF PERFORMANCE

10 Best Performing ETFs in March 2021			
	Stock Code	Name	Monthly Return (%)
1	3065	Xtrackers MSCI Singapore UCITS ETF	6.01
2	3027	Xtrackers MSCI Russia Capped Swap UCITS ETF	5.83
3	3165	BMO MSCI Europe Quality Hedged to USD ETF	5.65
4	3070	Ping An of China CSI HK Dividend ETF	4.49
5	3092	Xtrackers MSCI Thailand UCITS ETF	4.43
6	3160	BMO MSCI Japan Hedged to USD ETF	3.74
7	3140	Vanguard S&P 500 Index ETF	3.67
8	3143	BMO Hong Kong Banks ETF	3.48
9	3101	Vanguard FTSE Developed Europe Index ETF	3.29
10	3110	Global X Hang Seng High Dividend Yield ETF	2.98

10 Worst Performing ETFs in March 2021			
	Stock Code	Name	Monthly Return (%)
1	2826	Global X China Cloud Computing ETF	-14.85
2	3186	CICC KraneShares CSI China Internet Index ETF	-13.85
3	2812	Samsung CSI China Dragon Internet ETF	-12.08
4	3193	CSOP Yinhua CSI 5G Communications Theme ETF	-11.74
5	3182	W.I.S.E-Nasdaq Overseas China New Econ Co Top 50 Idx Tracker	-10.91
6	3191	Global X China Semiconductor ETF	-9.76
7	3032	Hang Seng TECH Index ETF	-9.51
8	3067	iShares Hang Seng TECH ETF	-9.37
9	3033	CSOP Hang Seng TECH Index ETF	-9.07
10	3088	ChinaAMC Hang Seng TECH Index ETF	-9.00

## L&I PRODUCT PERFORMANCE

3 Best Single-Day Returns in L&I Products in March 2021				
	Stock Code	Name	Date	Single-Day % Change
1	7552	CSOP Hang Seng TECH Index Daily (-2x) Inverse Product	8/3/2021	12.55%
2	7226	CSOP Hang Seng TECH Index Daily (2x) Leveraged Product	11/3/2021	10.98%
3	7552	CSOP Hang Seng TECH Index Daily (-2x) Inverse Product	4/3/2021	10.49%

3 Worst Single-Day Returns in L&I Products in March 2021				
	Stock Code	Name	Date	Single-Day % Change
1	7226	CSOP Hang Seng TECH Index Daily (2x) Leveraged Product	8/3/2021	-12.58%
2	7552	CSOP Hang Seng TECH Index Daily (-2x) Inverse Product	11/3/2021	-10.09%
3	7226	CSOP Hang Seng TECH Index Daily (2x) Leveraged Product	4/3/2021	-9.91%

### What are L&I Products?

Leveraged and Inverse Products (L&I Products) are structured like ETFs. A Leveraged Product amplifies the daily return of an index (by two times at max. in Hong Kong) while an Inverse Product delivers the opposite return of its benchmark on a daily basis.

L&I Products are constructed with derivatives, typically swaps or futures.

As L&I Products are tailored for day trading, their returns may deviate from the stated product objective if the holding period is longer than one day.

## Number of ETFs / L&I Products, ADT & MC in March 2021

Product Type	Underlying Market	Number of Products	ADT			MC		
			\$m	Market Share (%)	% Change	\$m	Market Share (%)	% Change
ETF	Mainland China A-Share	32	1,296	16.7	-12	67,003	17.0	-8
	Hong Kong Equity	21	4,691	60.6	-27	193,491	49.2	0
	Asia Pacific Equity	26	22	0.3	-33	31,381	8.0	-4
	Overseas Equity	24	103	1.3	-36	39,777	10.1	-2
	Fixed Income & Currency	14	11	0.1	-40	42,761	10.9	0
	Commodity	6	92	1.2	-37	4,438	1.1	-14
	ETF Total	123	6,215	80.3	-25	378,850	96.3	-2
L&I Product	Hong Kong Equity	11	1,379	17.8	18	8,821	2.2	-3
	Overseas Equity	6	68	0.9	25	1,811	0.5	-4
	Commodity	1	27	0.3	-25	1,768	0.4	2
	Mainland China A-Share	6	55	0.7	10	2,110	0.5	-8
	L&I Total	24	1,529	19.7	16	14,509	3.7	-4
<b>Total</b>		<b>147</b>	<b>7,744</b>	<b>100</b>	<b>-19</b>	<b>393,360</b>	<b>100</b>	<b>-2</b>

Note 1: Financial figures are expressed in Hong Kong dollars. L&I stands for Leveraged and Inverse.

Note 2: ETF and L&I Product Market Perspective covers ETFs and L&I Products listed and traded on HKEX's securities market. Multiple counters of an ETF / L&I Product are counted as one ETF / L&I Product. Market capitalisation statistics exclude SPDR Gold Trust. Performance statistics cover listed and traded ETFs only and are based on the closing prices. For ETFs with multiple counters, only the performance of the Hong Kong dollar counter is included. All data are as of month end.

Note 3: Past performance is not an indicator for future performance.

Note 4: Due to rounding, numbers presented in this document may not add up precisely to the totals provided.

### DISCLAIMER:

The information contained in this document is for general informational purposes only and does not constitute an offer, solicitation or recommendation to buy or sell any securities or to provide any investment advice or service of any kind. HKEX and/or its subsidiaries endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracy or omission or from any decision, action or non-action based on or in reliance upon information contained in this document.